Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 (DIMENSION)
Background and Objectives :
The presence of vitamin D deficiency in patients with type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular disease (CVD). We aim to see whether supplementation of vitamin D in these patients helps to improve the endothelial function (EF) a surrogate marker of CVD risk.
Hypothesis: Vitamin D supplementation in patients with T2DM and low serum 25(OH) D concentrations (<30ng/ml) will improve EF as measured by the Endo-PAT machine by 0.4 units (30% improvement over baseline) and/or will result in a increase of EPCs (CD133+/KDR+) and CD45dim CD34+/KDR.
The investigators will test this hypothesis by comparing 2 groups of T2DM patients randomized to placebo or vitamin D3 for 16 weeks.
This is a 16 weeks trial in which 120 T2DM patients will be screened with the aim to recruit 60 T2DM patients with vitamin D deficiency or insufficiency. Out of these 60 patients , 30 patients will be started on vitamin D supplementation and 30 patients will be given a matched placebo. Endothelial function (EF) will be checked before and after supplementation to see a change in EF.
Significance of Project:
If this study shows a significant improvement of EF, it would justify larger scale studies to show that vitamin D supplementation in patients with T2DM mitigates CVD risk and vitamin D supplementation in patients with T2DM and vitamin D deficiency to improve CVD risk.
Diabetes Mellitus Type 2
Vitamin D Deficiency
Drug: Vitamin D supplementation
Drug: Placebo Pill
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 and Low 25(OH)D Concentrations: Does it Help to Improve Endothelial Function-The DIMENSION TRIAL|
- Endothelial function as assessed by the reactive hyperemia index and endothelial progenitor cells [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]Endothelial function will be tested by using the EndoPAT machine which measures the reactive hyperemia index and by estimating the no. of endothelial progenitor cells in the peripheral blood by flow cytometry.
- Markers of endothelial cell activation and thrombogenesis [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]Biomarkers measured include hsCRP, e-selectin,von-willebrand factor(vWF)
- No. of circulating endothelial cells and endothelial microparticles [ Time Frame: 16-20 weeks ] [ Designated as safety issue: No ]The no. of circulating endothelial cells and endothelial microparticles will be estimated before and after intervention.
|Study Start Date:||September 2012|
|Estimated Study Completion Date:||July 2014|
|Estimated Primary Completion Date:||April 2014 (Final data collection date for primary outcome measure)|
Active Comparator: Vitamin D supplementation
Vitamin D3 tablets (cholecalciferol)
Drug: Vitamin D supplementation
Vitamin D3 marketed by oneNine57
Other Name: Vitamin D3-Cholecalciferol 1000units per tablet.
Placebo Comparator: Placebo pill
Drug: Placebo Pill
Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
Other Name: Placebo
Overall Aims: Type 2 Diabetes Mellitus (T2DM) is increasingly more prevalent in Singapore and is a high cardiovascular diseases (CVD) risk factor (1,2). The presence of low serum 25(OH)D concentrations (<30ng/ml) has also been classified as an independent predictor of CVD(3,4) and has been seen to be more prevalent in T2DM (5-7). We aim to see whether replacement with vitamin D in these patients helps to mitigate CVD risk. Since endothelial dysfunction is one of the earliest manifestations of CVD and is a very robust surrogate marker, we aim to measure the endothelial function (EF) before and after vitamin D supplementation to evaluate for beneficial impact on this endpoint.
Specific Aims: Although, there are some small scale studies done with a single high dose replacement of vitamin D2/D3, no studies have been done using regular daily supplementation with vitamin D3 and with measurement of EF using the Endo-PAT machine or measurement of endothelial progenitor cells (EPCs).We are doing this pilot study to see whether replacement with vitamin D results in an improvement of EF as measured using the Endo-PAT and estimation of EPCs and some biomarkers as independent established surrogate markers of CVD risk. The estimation of endothelial progenitor cells has been proposed as a surrogate marker of vascular dysfunction and is known to be reduced in patients with cardiovascular risk factors (8). The no. of circulating endothelial cells (CECs) and endothelial microparticles have been seen to be elevated in patients with cardiovascular risk factors and DM and has also been proposed as a effective surrogate marker. We aim to quantify the no. of endothelial progenitor cells (EPCs) staining positive for CD133+/KDR (kinase insert domain-containing receptor),CD34+/KDR and CD45dim CD34+/KDR , CECs (CD 146+/CD45- ) and EMPs derived from endothelial progenitors (CD45−/CD146+/CD34+/CD117+) and from mature endothelial cells (CD45−/CD146+/CD34+/CD117−).using flow cytometry.
Vitamin D supplementation in patients with T2DM and low serum 25(OH) D concentrations (<30ng/ml) will improve EF as measured by the Endo-PAT machine by 0.4 units (30% improvement over baseline) and/or will result in a increase of EPCs (CD133+/KDR+) and CD45dim CD34+/KDR. The investigators will test this hypothesis by comparing 2 groups of T2DM patients randomized to placebo or vitamin D3 for 16 weeks.
To explore the prevalence of low serum 25(OH) D concentrations (<30ng/ml) in T2DM patients and evaluate the difference in the EF in the two groups. To see whether vitamin D supplementation helps to further improve other parameters such as biomarkers, blood pressure, BMI, urine albumin-to-creatinine ratio (ACR), lipid profile of T2DM patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01741181
|Contact: Rinkoo Dalan, MBBS,FRCPfirstname.lastname@example.org|
|Tan Tock Seng Hospital||Recruiting|
|Singapore, Singapore, 308433|
|Contact: Rinkoo Dalan, MBBS,FRCP 65-81263176 email@example.com|
|Principal Investigator: Rinkoo Dalan, MBBS,FRCP|
|Principal Investigator:||Rinkoo Dalan, MBBS, FRCP||Tan Tock Seng Hospital|